EULAR® 2024 Insights

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

EULAR® 2024 Insights

Rheumatoid Arthritis
SLE
Osteoarthritis
Spondyloarthropathies
Crystal Arthropathies
Osteoporosis
Systemic and Connective Tissue Disease
Vasculitis
All Rheumatology

Playback speed

10 seconds

EULAR® 2024 Insights: Guselkumab Provides Durable Improvements in Pain Among Patients With Psoriatic Arthritis and an Inadequate Response to TNFi: COSMOS Phase 3b Trial

By EULAR® 2024 Insights FEATURING Laura Coates

48 views

June 21, 2024

Comments 0

Spondyloarthropathies

Highlights of EULAR 2024 in Spondyloarthritis and Psoriatic Arthritis

EULAR® 2024 Insights

K. Aouad

270 views

Clinical features of patients with SpA, with or without IBD: results…

EULAR® 2024 Insights

M. De Hooge

10 views

EULAR® 2024 Insights- Reasons for Non-response to Treatments in Pati…

EULAR® 2024 Insights

F. Coşan

8 views

EULAR® 2024 Insights: Reasons for Non-response to Treatments in Pati…

EULAR® 2024 Insights

F. Coşan

62 views

EULAR® 2024 Insights: Impact of Peripheral Arthritis on Disease Acti…

EULAR® 2024 Insights

C. Lopez-Medina

EULAR® 2024 Insights: Apremilast Treatment in Early Oligoarticular P…

EULAR® 2024 Insights

L. Gossec

14 views

EULAR® 2024 Insights: Associations Between Clinical Characteristics …

EULAR® 2024 Insights

E. R. Soriano

EULAR® 2024 Insights - Factors Associated with the Evolution of Dege…

EULAR® 2024 Insights

L. Pina Vegas

38 views

EULAR® 2024 Insights: Chronic Kidney Disease in Patients with Psoria…

EULAR® 2024 Insights

D. Gladman

65 views

EULAR® 2024 Insights: Guselkumab Provides Durable Improvements in Pa…

EULAR® 2024 Insights

L. Coates

48 views

EULAR® 2024 Insights: Spot on Treatment Failure in PsA: Where Are th…

EULAR® 2024 Insights

V. Chandran

104 views

EULAR® 2024 Insights - Sex-Related Differences in Trial Outcomes in …

EULAR® 2024 Insights

L. Eder

52 views

EULAR® 2024 Insights: Drug Survival of First-line TNF and Apremilast…

EULAR® 2024 Insights

A. Ogdie

80 views

EULAR® 2024 Insights - Enhancing the Diagnostic Accuracy and Avoidin…

EULAR® 2024 Insights

D. Poddubnyy

99 views